D
Centessa Pharmaceuticals plc
CNTA
$11.76
-$1.30-9.95%
D
Sell
7/12/2023Upgraded
Centessa Pharmaceuticals plc (CNTA) was upgraded to D- from E+ on 7/12/2023 due to a noticeable increase in the volatility index and total return index.
Centessa Pharmaceuticals plc (CNTA) was upgraded to D- from E+ on 7/12/2023 due to a noticeable increase in the volatility index and total return index.
E
Sell
3/14/2023Downgrade
Centessa Pharmaceuticals plc (CNTA) was downgraded to E+ from D- on 03/14/2023.
Centessa Pharmaceuticals plc (CNTA) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index.
D
Sell
11/16/2022Upgraded
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 11/16/2022 due to a major increase in the growth index and total return index. Operating cash flow increased 34.72% from -$59.88M to -$39.09M, EBIT increased 25.28% from -$65.61M to -$49.03M, and earnings per share increased from -$0.6871 to -$0.5711.
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 11/16/2022 due to a major increase in the growth index and total return index. Operating cash flow increased 34.72% from -$59.88M to -$39.09M, EBIT increased 25.28% from -$65.61M to -$49.03M, and earnings per share increased from -$0.6871 to -$0.5711.
E
Sell
8/12/2022Downgrade
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 8/12/2022 due to a decline in the growth index, solvency index and volatility index. EBIT declined 28.06% from -$51.24M to -$65.61M, the quick ratio declined from 20.87 to 15.07, and operating cash flow declined 19.71% from -$50.02M to -$59.88M.
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 8/12/2022 due to a decline in the growth index, solvency index and volatility index. EBIT declined 28.06% from -$51.24M to -$65.61M, the quick ratio declined from 20.87 to 15.07, and operating cash flow declined 19.71% from -$50.02M to -$59.88M.
D
Sell
8/5/2022Upgraded
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 8/5/2022 due to an increase in the volatility index and valuation index.
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 8/5/2022 due to an increase in the volatility index and valuation index.
E
Sell
7/19/2022Downgrade
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 7/19/2022 due to a decline in the volatility index and valuation index.
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 7/19/2022 due to a decline in the volatility index and valuation index.
D
Sell
6/30/2022Upgraded
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 6/30/2022 due to an increase in the volatility index.
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 6/30/2022 due to an increase in the volatility index.
E
Sell
6/10/2022Downgrade
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 6/10/2022 due to a decline in the volatility index and total return index.
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 6/10/2022 due to a decline in the volatility index and total return index.
D
Sell
5/23/2022Upgraded
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 5/23/2022 due to a noticeable increase in the growth index and solvency index. Operating cash flow increased 11.46% from -$56.49M to -$50.02M, earnings per share increased from -$0.6757 to -$0.6022, and EBIT increased 6.13% from -$54.58M to -$51.24M.
Centessa Pharmaceuticals Limited (CNTA) was upgraded to D- from E+ on 5/23/2022 due to a noticeable increase in the growth index and solvency index. Operating cash flow increased 11.46% from -$56.49M to -$50.02M, earnings per share increased from -$0.6757 to -$0.6022, and EBIT increased 6.13% from -$54.58M to -$51.24M.
E
Sell
4/18/2022Downgrade
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 4/18/2022 due to a noticeable decline in the growth index, efficiency index and total return index. Operating cash flow declined 70.3% from -$33.17M to -$56.49M, net income declined 51.5% from -$40.16M to -$60.84M, and earnings per share declined from -$0.4467 to -$0.6757.
Centessa Pharmaceuticals Limited (CNTA) was downgraded to E+ from D- on 4/18/2022 due to a noticeable decline in the growth index, efficiency index and total return index. Operating cash flow declined 70.3% from -$33.17M to -$56.49M, net income declined 51.5% from -$40.16M to -$60.84M, and earnings per share declined from -$0.4467 to -$0.6757.
D
Sell
11/4/2021Downgrade
Centessa Pharmaceuticals Limited (CNTA) was downgraded to D- from D on 11/4/2021 due to a noticeable decline in the volatility index.
Centessa Pharmaceuticals Limited (CNTA) was downgraded to D- from D on 11/4/2021 due to a noticeable decline in the volatility index.
D
Sell
8/23/2021None
Centessa Pharmaceuticals plc (CNTA) was downgraded to D from U on 08/23/2021.
Centessa Pharmaceuticals plc (CNTA) was downgraded to D from U on 08/23/2021.
NASDAQ
04/04/2025 12:55PM Eastern
Quotes delayed
